Santhera Pharmaceuticals Expands Reach with Exclusive Distribution Agreement for AGAMREE®

Pratteln, Switzerland, 19 August 2025 – Santhera Pharmaceuticals Holding AG (SIX: SANN), a leading biotechnology company specializing in neuromuscular and metabolic diseases, has announced an exclusive distribution agreement with Uniphar. This agreement will facilitate the distribution of AGAMREE® (vamorolone) across five Gulf Cooperation Council (GCC) countries: the United Arab Emirates, Saudi Arabia, Kuwait, Oman, and Bahrain. The drug is intended for the treatment of Duchenne muscular dystrophy (DMD) in patients aged four years and older.

The distribution of AGAMREE® is set to commence in the first quarter of 2026 through a “Named-Patient Program.” This initial phase will allow for targeted distribution to specific patients, ensuring that those in need have early access to the therapy. Following this, broader commercial sales are anticipated by the end of 2026, contingent upon market authorization and pricing agreements.

Santhera Pharmaceuticals will receive a percentage of net sales as compensation, in line with its existing distribution agreements. This strategic partnership is expected to enhance patient access to AGAMREE® in the GCC region, providing a critical treatment option for those affected by DMD.

As of 17 August 2025, Santhera Pharmaceuticals’ share price closed at CHF 13.9 on the SIX Swiss Exchange, with a market capitalization of CHF 184.1 million. The company’s financial performance has seen fluctuations, with a 52-week high of CHF 17.76 on 12 February 2025 and a low of CHF 7.21 on 17 November 2024. The price-to-earnings ratio stands at -3.77, reflecting the company’s current financial metrics.

This agreement marks a significant step for Santhera Pharmaceuticals in expanding its global footprint and underscores its commitment to addressing unmet medical needs in neuromuscular and metabolic diseases.